[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338625-105":59,"doc-detail-338625-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","foxp3cd8-ratio-associated-with-aggressive-behavior-in-runx3-methylated-diffuse-esophagogastric-junction-tumor","FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor","","Tumor immune microenvironment is increasingly central to treatment strategies for aggressive cancers, as regulatory T cells (Tregs) can dampen cytotoxic T-cell (CD8+) responses. This study tests whether the intratumoral and invasive-margin proportions of FOXP3+ Tregs and CD8+ cells predict outcomes in diffuse, non-EBV/non-MSI-high gastroesophageal adenocarcinomas. Ratios were quantified in 303 chemo-naive cases, and tumor histology modified prognosis. A higher invasive-margin FOXP3+/CD8+ ratio correlated with RUNX3 methylation and poor survival in the diffuse subtype, suggesting immune escape linked to CCL28.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/foxp3cd8-ratio-associated-with-aggressive-behavior-in-runx3-methylated-diffuse-esophagogastric-junction-tumor/338625/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/foxp3cd8-ratio-associated-with-aggressive-behavior-in-runx3-methylated-diffuse-esophagogastric-junction-tumor/338625.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main hypothesis of this study regarding FOXP3 and CD8+ cells?","Question",{"text":112,"@type":113},"The study hypothesized that the proportions of FOXP3+ Tregs and CD8+ cells are prognostically relevant in diffuse, non-EBV/non-MSI-high gastroesophageal adenocarcinomas characterized as more aggressive and immunologically inactive.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the FOXP3+/CD8+ ratio measured in the tumors?",{"text":117,"@type":113},"FOXP3+/CD8+ expression ratios were calculated at both the intratumoral region and the invasive margin using digital image–based cell counting from 303 chemo-naive non-EBV/non-MSI-high EGJ adenocarcinomas.",{"name":119,"@type":110,"acceptedAnswer":120},"What does a high invasive-margin FOXP3+/CD8+ ratio indicate for patients with RUNX3-methylated diffuse tumors?",{"text":121,"@type":113},"A high invasive-margin FOXP3+/CD8+ ratio was associated with RUNX3 methylation and poor prognosis in the RUNX3-methylated diffuse histological subtype, suggesting tumor immune escape potentially via CCL28.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338625,1790860184,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Received: 5 June 2024  \nRevised: 21 September 2024  \nAccepted: 3 October 2024  \nDOI: 10. 1111/cas.16373  \nOR I G I NAL ART I C L E  \nFOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor  \nSuguru Maruyama1 | Yu Imamura1  | Tasuku Toihata2 | Ikumi Haraguchi3 | Manabu Takamatsu4  | Makiko Yamashita5 | Yuichiro Nakashima6 | Eiji Oki6  | Kenichi Taguchi7 | Manabu Yamamoto8 | Shinji Mine9 | Akihiko Okamura1 | Jun Kanamori1 | Souya Nunobe1 | Takeshi Sano1 | Shigehisa Kitano5  | Tetsuo Noda3 | Masayuki Watanabe1  \n1Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan 2Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan 3Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan  \n4Department of Pathology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan  \n5Advanced Medical Development Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan 6Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan  \n7Department of Pathology, Kyushu Cancer Center, National Hospital Organization, Fukuoka, Japan  \n8 Department of Gastroenterological Surgery, Kyushu Cancer Center, National Hospital Organization, Fukuoka, Japan 9Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo, Japan  \nCorrespondence  \nYu Imamura, Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Kotoku, Tokyo 135-8550, Japan. [Email:](Email: yu.imamura@jfcr.or.jp)[ yu.imamura@jfcr.or.jp](Email: yu.imamura@jfcr.or.jp)  \nFunding information  \nJapan Society for the Promotion of Science, Grant/Award Number:  \nJP19K09161, JP19K09231, JP20K09046 and JP24K11921; Uehara Memorial Foundation; Japan Research Foundation for Clinical Pharmacology; Foundation for Promotion of Cancer Research  \nAbstract  \nThe tumor immune microenvironment is increasingly becoming a key consideration in developing treatment regimens for aggressive cancers, with evidence that regulatory T cells (Tregs) attenuate the antitumor response by interrupting cytotoxic T cells (CD8+) . Here, we hypothesized the prognostic relevance of the proportions of Tregs (marked by forkhead box protein 3 [FOXP3]) and CD8+ cells in diffuse, nonEpstein–Barr virus (EBV)/non-microsatellite instability (MSI)-high gastroesophageal adenocarcinomas (GEAs), which are clinically characterized as more aggressive, immunologically inactive tumors as compared with their intestinal counterparts. Cell-count ratios of FOXP3+/CD8+ expression were calculated at the intratumoral region and invasive margin discretely on digital images from 303 chemo-naive nonEBV/non-MSI-high esophagogastric junction (EGJ) adenocarcinomas. A significant modifying prognostic effect of tumor histology was observed between 5-year EGJcancer-specific survival and the FOXP3+/CD8+ ratio at the invasive margin in pStage  \nAbbreviations: CI, confidence interval; COL2A, collagen 2A1 gene; EBER, Epstein–Barr virus-encoded RNA; EBV, Epstein–Barr virus; EGJ, esophagogastric junction; FFPE, formalinfixed, paraffin-embedded; FOXP3, forkhead box protein 3; GEA, gastroesophageal adenocarcinoma; HR, hazard ratio; IHC, immunohistochemical; ISH, in situ hybridization; MSI, microsatellite instability; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PMR, programmed death-1percentage of the methylated reference; TCGA, The Cancer Genome Atlas; TPS, tumor proportion score; Treg, regulatory T cell; UICC, Union for International Cancer Control.  \nSuguru Maruyama and Yu Imamura contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which p","cbCairQKHXEUcUcK","https://ap.wps.com/l/cbCairQKHXEUcUcK","pdf",1491383,14,"English","# Abstract\n## Methods and patient cohort\n## Prognostic findings and tumor histology interaction\n## Mechanistic interpretation and associated pathways","[{\"question\":\"What was the main hypothesis of this study regarding FOXP3 and CD8+ cells?\",\"answer\":\"The study hypothesized that the proportions of FOXP3+ Tregs and CD8+ cells are prognostically relevant in diffuse, non-EBV/non-MSI-high gastroesophageal adenocarcinomas characterized as more aggressive and immunologically inactive.\"},{\"question\":\"How was the FOXP3+/CD8+ ratio measured in the tumors?\",\"answer\":\"FOXP3+/CD8+ expression ratios were calculated at both the intratumoral region and the invasive margin using digital image–based cell counting from 303 chemo-naive non-EBV/non-MSI-high EGJ adenocarcinomas.\"},{\"question\":\"What does a high invasive-margin FOXP3+/CD8+ ratio indicate for patients with RUNX3-methylated diffuse tumors?\",\"answer\":\"A high invasive-margin FOXP3+/CD8+ ratio was associated with RUNX3 methylation and poor prognosis in the RUNX3-methylated diffuse histological subtype, suggesting tumor immune escape potentially via CCL28.\"}]","FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor | PDF",1790024673,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/961a1a6a6601d9f2cedf3ec8d1f4623a.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bd97741570f38f9eb2eb4db953c67d2.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e42ab2a01b1e06731724b7129310339d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd5018345d78327c6fdb00314fe85d90.webp",980,1287]